NCT01770483View on ClinicalTrials.gov

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Hepatitis C, ChronicDIABETES MELLITUS Type 2
Interventions
DRUG

nitazoxanide

nitazoxanide 500mg twice daily

DRUG

conventional interferon alfa

Inj interferon 3 Million International Units thrice weekly

DRUG

Ribavirin

ribazole

Trial Locations (1)

Unknown

Endocrinology and Diabetes management centre, Lahore

Sponsors

Collaborators (1)

Getz Pharma
All Listed Sponsors
collaborator

Getz Pharma

INDUSTRY

lead

Services Institute of Medical Sciences, Pakistan

OTHER_GOV